Tag: PDF

Allschwil, Switzerland – June 26, 2026
Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously announced senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP.

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4^th floor, 75013 Paris, France.

NEW YORK, 25 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour développer des thérapies cellulaires et géniques, a tenu son assemblée générale mixte ce jour à 14h30, heure de Paris, à l’auditorium du site Biopark, situé au 11 rue Watt, 4^ème étage, 75013 Paris, France.

New York, United States, June 25, 2026 (GLOBE NEWSWIRE) -- The partnership strengthens the network where institutional deal flow converges and follows the onboarding of CBRE, JLL, Cushman & Wakefield, Avison Young and others over the past 18 months

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- The Kevin Kuykendall Grant for Student Athletes officially opens its application cycle, offering a dedicated financial award to undergraduate students nationwide who balance academic pursuits with athletic ambitions. Founded by seasoned entrepreneur and former professional baseball player Kevin D. Kuykendall, this initiative supports the next generation of sports industry leaders, including competitive athletes, future coaches, and aspiring sports management professionals.